<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167280</url>
  </required_header>
  <id_info>
    <org_study_id>Bio REB 1522</org_study_id>
    <nct_id>NCT04167280</nct_id>
  </id_info>
  <brief_title>Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma</brief_title>
  <official_title>Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is looking at the development of tolerance to methacholine following regular use of
      ipratropium bromide in mild asthmatics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted people with well controlled (mild) asthma to determine if
      ipratropium bromide taken three times daily for six days (i.e. 2 puffs in the morning, 2
      puffs in the afternoon and 2 puffs in the evening) followed by a final dose on the morning of
      day 7 reduces the effectiveness of this medication on blocking the effect of methacholine
      challenge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Actual">March 13, 2020</completion_date>
  <primary_completion_date type="Actual">March 13, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methacholine PD20</measure>
    <time_frame>Pre treatment</time_frame>
    <description>dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in one second)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Methacholine PD20</measure>
    <time_frame>Day 7 after starting treatment</time_frame>
    <description>dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in one second)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Methacholine PD20</measure>
    <time_frame>24 hours after last dose</time_frame>
    <description>dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in one second)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Ipratropium bromide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mcg bronchodilator inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching bronchodilator inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium Metered Dose Inhaler</intervention_name>
    <description>MDI to deliver 20mcg per puff ipratropium bromide</description>
    <arm_group_label>Ipratropium bromide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo metered dose inhaler</intervention_name>
    <description>matched MDI to deliver inactive drug</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  airway responsiveness to methacholine

          -  adequate baseline lung function

          -  no respiratory infection or exposure to stimuli that may alter response to
             methacholine within 4 weeks

        Exclusion Criteria:

          -  pregnancy

          -  current smoker

          -  requirement for medications other than salbutamol that will interfere with airway
             response to methacholine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Cockcroft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Don Cockcroft</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ipratropium bromide</keyword>
  <keyword>methacholine PD20</keyword>
  <keyword>tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

